



Thursday, 28 January 2010

3M REQUESTS 60 DAY EXTENSION TO MTA

OBJ Limited (ASX: OBJ) announced on 4 November 2009 that initial in vitro testing by 3M was expected to be completed by 1 February 2010.

The testing undertaken by 3M required an extension of time to the initial agreement.

OBJ now advises that it has granted the extension to the Materials Transfer Agreement (MTA) to 3M Corporation to allow for the completion of additional testing.

3M is an American multinational corporation with 79,000 employees operating in 60 countries generating global sales in excess of US\$25 billion in 2008.

The Materials Transfer Agreement sets the parameters for an initial in vitro testing program to evaluate the performance of the eM-patch® technology in conjunction with 3M drug delivery platforms and proprietary formulations.

The Company will update shareholders on progress of the program.

- Ends -

For more information:

Mr Glyn Denison Director

P +618 9443 3011

E info@obj.com.au

W www.obj.com.au

About OBJ:

OBJ Ltd is an early stage drug and cosmetic delivery company focused on the development and commercialization of transdermal and transmembrane patches and applicator technologies. OBJ develops low-cost, high-performance patch and applicator products and undertakes partner funded developments using the Company's dermaportation and eM-patch® technologies. OBJ's business focus is the development of new products for supply or licencing and providing feasibility assessments, patch formulations, testing and intellectual property development services to partner companies.

About OBJ's Technologies

OBJ's proprietary technologies utilise magnetic field and magnetic array processes to enhance the delivery of therapeutic and beneficial compounds. OBJ's technologies have been shown in multi-centred university studies and independent commercial evaluations to enhance transdermal drug delivery of a wide a wide range of commercially significant drugs and peptides.